Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
acute lymphoblastic leukemia
Biotech
Merck pays $700M for bispecific challenger to Amgen cancer drug
The deal will give Merck global rights to Curon's CD3xCD19 bispecific, positioning it as a rival to Amgen, AstraZeneca and Cullinan Therapeutics.
Nick Paul Taylor
Aug 9, 2024 8:52am
Autolus outlines path to FDA after CAR-T trial hits endpoint
Dec 9, 2022 9:15am
New study bolsters support for novel 'off-the-shelf' CAR-T cells
Apr 25, 2022 11:30am
Blackstone bets on Autolus' CD19 CAR-T in $250M deal
Nov 8, 2021 7:15am
Erytech's eryaspase flunks late-stage pancreatic cancer trial
Oct 25, 2021 10:52am
Takeda blood cancer drug flunks phase 3 in setback to R&D plans
Sep 2, 2021 8:55am
